**To the Editor:** *Mycoplasma* spp. are well-known pathogens in human and veterinary medicine. Mammals, especially primates and including humans, share similar or even identical *Mycoplasma* spp., which might be commensal or pathogenic ([@R1]). Additionally, sporadic infections of immunocompromised persons with *Mycoplasma* spp. that originated from domestic animals have been reported ([@R1]); susceptibility in this human population is increased ([@R2],[@R3]). *M. phocicerebrale* is the only *Mycoplasma* pathogen of animals that regularly infects humans, causing a disease called seal fingers ([@R1],[@R4]). However, we report a human infection with an avian *Mycoplasma* organism.

A clinical trial to investigate the capability of *M. lipofaciens* (strain ML64) ([@R5]) to spread horizontally between infected and noninfected turkey poults in an incubator demonstrated airborne transmission of the pathogen within 24 hours ([@R6]). During the trial, the veterinarian conducting the study, a 36-year-old man, was monitored for infection. Each day, 2 swabs were taken from both nostrils, starting from the day before the infected poults hatched (day 0) through day 7 after the poult hatching date. When handling eggs and poults, the veterinarian wore gloves but not a protective mask. Two days after the poults hatched (day 3), the veterinarian reported throat pain and a slight rhinitis, which indicated a respiratory disease. The next day only the rhinitis with minor nasal pain was present.

One nasal swab from each sampling day was used for *Mycoplasma* spp. culture ([@R5]). Isolated *Mycoplasma* organisms were subjected to an immunobinding assay ([@R6]) with antiserum against *M. lipofaciens*, *M. buteonis*, *M. falconis*, *M. gypis*, *M. gallisepticum*, *M. meleagridis*, *M. synoviae,* and *M. iowae,* selected because the veterinarian regularly handled these isolates. The second nasal swab from each sampling day was taken to detect *Mycoplasma* DNA by PCR ([@R5]). The samples for PCR testing were stored at --20°C and tested only when attempts to isolate *Mycoplasma* spp. failed.

Six weeks after the infection, a serum sample from the patient was examined for specific antibodies against *M. lipofaciens* by 3 different methods: modified immunobinding assay ([@R6]) (which used patient's serum and peroxidase-conjugated goat-antihuman serum \[STAR90P, Serotec Ltd, Oxford, UK\]), a growth inhibition test, and antibody titers of serum dilutions. The first 2 methods used *M. lipofaciens* (strain ML64) from a turkey trial ([@R6]) and the reference strains of *M. buteonis* (Bb/T2g) and *M. falconis* (H/T1). For the third method, to determine the titer, 2-fold serial dilutions of the patient's serum samples were prepared and incubated with a bacterial suspension (*M. lipofaciens* strain ML64) containing 3.2 × 10^2^ CFU. The antibody titer was based on the highest serum dilution capable of reducing 50% of the mean CFU count.

Before the infected poults hatched, attempts to isolate *Mycoplasma* organisms and demonstrate *Mycoplasma* DNA from the nasal swabs were unsuccessful. However, from the day of hatching (day 1) until 3 days later (day 4), *Mycoplasma* organisms were isolated from the nasal swabs and identified as *M. lipofaciens*. On day 5, only *Mycoplasma* DNA was demonstrated ([Table](#T1){ref-type="table"}). Specific antibodies against *M. lipofaciens* (strain ML64) were detected by using the immunobinding assay and growth inhibition test. Antibodies against other *Mycoplasma* spp. were not detected. Antibody titer against *M. lipofaciens* was 128.

###### Timeline of natural infection of veterinarian with *Mycoplasma lipofaciens* (strain ML64) from infected poults\*

  Finding          Day                                                                                                   
  ---------------- ------ --------- --------- ------------------------------ ----------------------------- ------ ------ ------
  Isolation        --     *M. l.*   *M. l.*   *M. l.*                        *M. l.*                       --     --     --
  PCR result‡      --     ND        ND        ND                             ND                            \+     --     --
  Clinical signs   None   None      None      Throat pain, slight rhinitis   Slight rhinitis, nasal pain   None   None   None

\*--, negative; *M.l., Mycoplasma lipofaciens* (identified by immunobinding assay); ND, not done; +, positive. †Hatching of infected poults and demonstration of aerosol transmission among poults. ‡Detection of mycoplasma DNA per Lierz et al. ([@R5]).

*M. lipofaciens* have been reported from a chicken, turkey, duck ([@R7],[@R8]), and a raptor egg ([@R5]). Strain ML64 is highly pathogenic for chicken and turkey embryos and can be transmitted by air ([@R6],[@R9]). The veterinarian handling the infected poults was free of nasal *Mycoplasma* organisms a day before contact. His infection occurred concurrent with demonstration of airborne transmission among poults. The isolation of *M. lipofaciens* from his nares for 4 days demonstrates the infectivity and reproductive capability of this *Mycoplasma* strain in humans: as a pure contaminant, isolation for several days would be unlikely. Christensen et al. ([@R10]) have reisolated different avian *Mycoplasma* strains (*M. gallisepticum*, *M. synoviae*, *M. iowae*) from a human nose, from 12 hours through 1 day after artificial infection, demonstrating differences between avian strain abilities to survive on human mucosa. *M. lipofaciens* invasiveness for humans is underscored by finding specific antibodies against this species 6 weeks after infection. Cross-reactivity to other *Mycoplasma* spp. cannot be excluded but seems unlikely.

This study suggests that *M. lipofaciens* (strain ML64) can be transmitted successfully to humans and may cause clinical symptoms; the study documents nonartificial human infection with an avian *Mycoplasma* sp. These findings should be considered especially for humans highly susceptible to *Mycoplasma* infections, including children and persons with congenital or acquired immunodeficiencies ([@R2],[@R3]).
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